Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial medical
technology company that designs, produces and markets safe and effective
tissue care products based upon the Microcyn® Technology platform, today
unveiled Microcyn Solution with preservatives, at the New York Podiatric
Clinical Conference & Exhibition being held in downtown Manhattan,
The Microcyn® Solution for professional use is intended for the
irrigation and management via debridement of post-surgical wounds.
Available in 500 mL and 990 mL units with attached pharmasling® hangers,
Microcyn Solution has no known drug/treatment interactions or
contraindications; is non-foaming and safe to use around nose, mouth and
eyes; does not contain antibiotics and will not facilitate bacterial
resistance. With a laboratory-proven inactivation of bacteria, fungus
and spores in-solution, Microcyn delivers a six-log reduction of MRSA,
VRE, Pseudomonas, Acinetobacter and many other pathogens
in just 30 seconds as labeled and cleared by the FDA. The patented
Microcyn Solution can be easily and harmlessly disposed of without the
added cost of special handling. The Microcyn Technology has treated over
two million patients worldwide and has been used in 30 clinical studies,
all without a report of a single serious adverse effect.
For more information, pricing or ordering visit http://store.oculusis.com/
or phone 1-800-931-3205.
Adam Landsman, DPM, Ph.D. and assistant professor of surgery at Harvard
Medical School in Boston, who was lead investigator in a Phase II trial
in which the Microcyn Technology was used to treat mildly infected
diabetic foot ulcers in 2007, stated: "The current standard for surgical
wound cleansing and irrigation involves the use of products that do not
kill the MRSA infection in-vitro. This is important in light of the
skyrocketing proliferation of these dangerous bacteria as well as the
evolving 'super bug' mutations. Microcyn is also highly attractive since
it does not produce foam, which hampers visualization of the wound. And
finally, with the health community so vitally focused on cost savings,
the Microcyn Solution will actually cost less than the current
combination of saline and expensive antibiotics."
Oculus is initially introducing the Microcyn Solution with a 14-person
sales force, which will be expanded as the company addresses this
growing healthcare challenge. According to Medtech Insight, Inc, there
were 39 million acute surgeries and nine million trauma wounds in the
United States alone in 2004.
Source Oculus Innovative Sciences